LUGANO, 22 February 2018 – The TAT (Targeted Anticancer Therapies) International Congress 2018 will take place in Paris, France where around 450 attendees from all over the world are expected to join what is renowned to be “the home of phase I in oncology.” (1)
“The TAT Congress provides a glimpse into the future of cancer care, focussing on early stage drug development and translational research.” said Giuseppe Giaccone, TAT Congress Scientific Committee Chair, “The goals and design of phase I trials have changed, still encompassing safety and toxicity, they also now include clinical activity / response and biomarkers research.”
The TAT International Congress brings together basic scientists, physicians and translational researchers from academic settings, industry and regulatory agencies for the common aim of speeding up the development of new anti-cancer treatment for the benefit of cancer patients.
The TAT 2018 programme (2) will cover the most promising new drugs and targets under development in early phase clinical and translational research, and drugs close to entering clinical development.
Sessions are devoted to among others novel immuno targets, epigenetics targets, metabolic targets, and cell cycle targets; multiple ways to harness targeting DNA to treat cancer, novel topoisomerase inhibitors and precision
Article originally posted at